MedTrace Logo

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

NCT02249052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-02-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether collagenase is effective in reducing the surface area of a subcutaneous benign lipoma.

Conditions

  • Lipoma

Interventions

DRUG

AA4500

Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously

DRUG

placebo

Placebo

Sponsors & Collaborators

  • Advance Biofactures Corporation

    collaborator INDUSTRY

  • Gerut, Zachary, M.D.

    lead INDIV

Principal Investigators

  • Zachary E Gerut, MD · Private Practice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-04-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249052 on ClinicalTrials.gov